Skip to Content
Discovering the causes of cancer and the means of prevention

Lymphoproliferative Malignancies: Registry-Based Studies in Sweden and Denmark

Numerous clinical reports and population or hospital-based surveys have reported familial aggregations of non-Hodgkin lymphoma (NHL), Hodgkin lymphoma, multiple myeloma, and chronic lymphocytic leukemia (CLL). The occurrence of more than one type of lymphoproliferative malignancy within the same family has also been described in case-control studies. The availability of register databases in Sweden and Denmark providing nationwide information on family cancer, hospitalization for medical conditions, cancer incidence, comprehensive population listings, and vital status and cause of death for deceased persons offer the unique opportunity to examine familial aggregation of lymphoproliferative malignancies and autoimmune diseases.

In very large case-control studies of first-degree relatives of cases with specific lymphoproliferative malignancies compared with first-degree relatives of controls, investigators in DCEG have found that first-degree relatives (N=70,006) of NHL cases (N=26,089) had modest to moderately increased risks of CLL, Hodgkin lymphoma, and NHL; relatives (N=14,336) of CLL cases (N=5,918) had significantly 7.5-fold increased risk of CLL, and smaller increases of NHL and Hodgkin lymphoma; relatives (N=22,984) of Hodgkin lymphoma cases (N=7,476) had significantly elevated risk of Hodgkin lymphoma, CLL, and NHL; but first-degree relatives (22,490) of multiple myeloma cases (N=8,406) did not have increased risks of lymphoproliferative malignancies other than multiple myeloma. Studies continue to assess:

  • Familial aggregation of lymphoproliferative and myeloproliferative hematologic malignancies and related precursor conditions
  • Family and personal history of immune-related and inflammatory disorders and risk of hematologic neoplasms
  • Disease characteristics and outcomes for familial hematologic malignancies and related precursor conditions.

For more information, contact Lynn Goldin or Martha Linet.

Integrative Tumor Epidemiology Branch - Research Areas

Radiation Epidemiology Branch - Research Areas